RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Hansa Biopharma Dividend 2024

Hansa Biopharma Dividend

0 SEK

Hansa Biopharma Dividend yield

Ticker

HNSA.ST

ISIN

SE0002148817

WKN

A0M65T

How much dividend does Hansa Biopharma 2024 pay?

According to the latest status from May 2024, Hansa Biopharma paid a total of 0 SEK per share in dividends within the last 12 months. With the current Hansa Biopharma price of 38.66 SEK, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Hansa Biopharma Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Hansa Biopharma Dividend Safe?

Hansa Biopharma has been increasing the dividend for 0 years.

Over the past 10 years, Hansa Biopharma has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Hansa Biopharma's Dividend Distributions

Hansa Biopharma’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Hansa Biopharma's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Hansa Biopharma's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Hansa Biopharma’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Hansa Biopharma Aktienanalyse

What does Hansa Biopharma do?

Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases. Hansa Biopharma is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Hansa Biopharma Stock

How much dividend does Hansa Biopharma pay?

Over the past 12 months, Hansa Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hansa Biopharma is expected to pay a dividend of 0 SEK.

What is the dividend yield of Hansa Biopharma?

The current dividend yield of Hansa Biopharma is .

When does Hansa Biopharma pay dividends?

Hansa Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hansa Biopharma?

Hansa Biopharma paid dividends every year for the past 0 years.

What is the dividend of Hansa Biopharma?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hansa Biopharma located?

Hansa Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hansa Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hansa Biopharma from 5/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/22/2024.

When did Hansa Biopharma pay the last dividend?

The last dividend was paid out on 5/22/2024.

What was the dividend of Hansa Biopharma in the year 2023?

In the year 2023, Hansa Biopharma distributed 0 SEK as dividends.

In which currency does Hansa Biopharma pay out the dividend?

The dividends of Hansa Biopharma are distributed in SEK.

Andere Kennzahlen von Hansa Biopharma

Our stock analysis for Hansa Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hansa Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.